Navigation Links
EpiCast Report: Methicillin-Resistant Staphylococcus Aureus (MRSA) - Epidemiology Forecast to 2024
Date:12/29/2015

NEW YORK, Dec. 29, 2015 /PRNewswire/ -- 

Summary

The Staphylococcus aureus bacterium, which was discovered in the 1880s, is a common cause of painful skin and soft tissue infections (SSTIs). The discovery of penicillin in 1928 allowed for the routine and successful treatment of S. aureus infections. However, in the late 1940s and throughout the 1950s, S. aureus developed resistance to penicillin. Another form of penicillin, called methicillin, was introduced to counter the increasing problem of penicillin-resistant S. aureus. However, beginning in the 1960s, some strains of S. aureus began demonstrating resistance to methicillin, resulting in what is now known as methicillin-resistant Staphylococcus aureus (MRSA), which is resistant to all beta-lactam antibiotics, including penicillin, methicillin, and amoxicillin. Thus, MRSA has evolved from a controllable nuisance into a serious public health concern.

For this analysis, GlobalData epidemiologists defined MRSA as bacterial infections caused by methicillin-resistant S. aureus. These bacteria are resistant to beta-lactam antibiotics, such as methicillin, amoxicillin, penicillin, and oxacillin. This analysis only includes hospitalized MRSA cases arising from the following infections: pneumonia, SSTIs, and BSIs. The International Classification of Diseases, Tenth Revision (ICD-10), code for MRSA infections (unspecified site) is A49.02.

In 2014, there were a total of 797,883 hospitalized incident cases of MRSA in the 7MM. GlobalData epidemiologists forecast that the hospitalized incident cases of MRSA in the 7MM will increase to 884,727 cases by 2024 at an Annual Growth Rate (AGR) of 1.09%. The number of hospitalized incident cases of MRSA in the US, France, Italy, Spain, UK, and Japan will increase, with AGRs ranging from 0.14% (Italy) to 3.54% (Japan), but will decrease in Germany, with a negative AGR of 0.19%.

Scope

- The Methicillin-Resistant Staphylococcus aureus (MRSA) EpiCast Report provides an overview of the risk factors and global trends of MRSA in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). provides an overview of the risk factors, comorbidities, and the global and historical trends for MRSA in the 7MM and includes a 10-year epidemiological forecast for the hospitalized incident cases of MRSA, segmented by sex, age, infection site (pneumonias, SSTIs, and bloodstream infections [BSIs]), and case definition (HA-MRSA and CA-MRSA), in these markets.
- The MRSA epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The MRSA EpiCast series will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global MRSA market.
- Quantify patient populations in the global MRSA market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for MRSA therapeutics in each of the markets covered.
- Identify the percentage of MRSA hospitalized incident cases by infection site and case definition.
Read the full report: http://www.reportlinker.com/p03411259-summary/view-report.html

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com

Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001


'/>"/>
SOURCE Reportlinker
Copyright©2015 PR Newswire.
All rights reserved


Related medicine technology :

1. EpiCast Report: Gram-Negative Bacterial Pneumonia - Epidemiology Forecast to 2022
2. EpiCast Report: Atrial Fibrillation - Epidemiology Forecast to 2023
3. EpiCast Report: Age-Related Macular Degeneration - Epidemiology Forecast to 2023
4. EpiCast Report: Breast Cancer (HER2-, HER2+) - Epidemiology Forecast to 2023
5. EpiCast Report: Diabetic Macular Edema - Epidemiology Forecast to 2023
6. EpiCast Report: Sepsis - Epidemiology Forecast to 2023
7. EpiCast Report: Peripheral Arterial Disease - Epidemiology Forecast to 2024
8. EpiCast Report: Gaucher Disease - Epidemiology Forecast to 2024
9. Report: Upgrading Medicaid Drug Benefits Could Save Pennsylvania $896 Million
10. BioMEMS 2013 Report: Microsystem Device Market for Healthcare Applications
11. New Oral Anticoagulants Markets Research Report: New Anticoagulants and their Manufacturers Covered
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2018)... ... 15, 2018 , ... During a special ceremony at the ... Illinois, was named the grand prize winner of the 2018 IsaBody Challenge®. The ... a global health and wellness company providing nutrition and lifestyle solutions. , ...
(Date:8/14/2018)... ... August 14, 2018 , ... ... commitment of more than $270,000 to expand a popular pet therapy program. ... full-time coordinator to facilitate more visits to patients throughout the hospital and outpatient ...
(Date:8/11/2018)... ... August 10, 2018 , ... Last month, Dr. Tim Herman, ... to deliver dental care in underserved communities surrounding its capital of Asunción. Along with ... Dr. Herman volunteered his time to help deliver care to over 550 individuals in ...
Breaking Medicine Technology:
(Date:8/11/2018)... , ... August 10, 2018 , ... Dr. Siavash Eftekhari, ... to Asunción, Paraguay for a week-long international outpost trip to deliver dental care in ... colleagues and support staff, Dr. Eftekhari volunteered his time to help deliver care to ...
(Date:8/11/2018)... (PRWEB) , ... August 10, 2018 , ... ... known for providing innovative procedures to metro Atlanta. Drs. Brent Sharpe and Froylan ... Northeast Georgia Medical Center in Braselton. , On June 27, the physicians combined ...
(Date:8/9/2018)... ... 2018 , ... Lyme disease is one of the fastest growing epidemics to ... – a 25-fold increase since surveillance began in 1982. According to a new report ... states and the District of Columbia. Yet, Lyme and other insect borne illnesses are ...
(Date:8/9/2018)... ... , ... RiverGlade Capital (“RiverGlade”), is pleased to announce that ... exclusive relationship with the firm. As an Operating Partner, Mr. Hudak will ... deal origination, evaluation and diligence. He brings a wealth of healthcare industry ...
(Date:8/7/2018)... RAPIDS, Mich. (PRWEB) , ... August 07, 2018 , ... ... has partnered with Blue Sky Vision. Michael Sussex, OD, founded the practice in Coldwater, ... Dr. Sussex practices with Matt Austin, OD, to offer comprehensive eye health services for ...
Breaking Medicine News(10 mins):